知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

300 条记录 (耗时 0.043 秒)

    miR-193a-3p and associated genes predict tumorigenesis and chemotherapy outcomes
    142.
    发明授权
    miR-193a-3p and associated genes predict tumorigenesis and chemotherapy outcomes 有权
    miR-193a-3p和相关基因预测肿瘤发生和化疗结果

    公开(公告)号：US09127320B2

    公开(公告)日：2015-09-08

    申请号：US13829903

    申请日：2013-03-14

    申请人： Jingde Zhu

    发明人： Jingde Zhu

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  A61K31/513 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57484 ,  G01N2800/52 ,  G01N2800/54

    摘要： The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection.

    摘要翻译： 本公开提供了可以通过其甲基化状态调节的miR-193a基因的表达水平与癌细胞的肿瘤发生和抗细胞对基于嘧啶抗代谢药（5-FU）的化学疗法的抗性之间的相关性。 除了甲基化状态和miR-193a的表达外，其下游基因如E2F1，SRSF2和凋亡基因如半胱天冬酶2也有作用，可作为癌症治疗预后和治疗选择的有用标志物。

    Means and Methods for Diagnosing Recurrence of Prostate Cancer After Prostatectomy
    143.
    发明申请
    Means and Methods for Diagnosing Recurrence of Prostate Cancer After Prostatectomy 审中-公开
    前列腺切除术后前列腺癌复发的手段和方法

    公开(公告)号：US20150241406A1

    公开(公告)日：2015-08-27

    申请号：US14432279

    申请日：2013-10-02

    申请人： METANOMICS HEALTH GMBH ,  CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

    发明人： Regina Reszka ,  Beate Kamlage ,  Bianca Bethan ,  Klaus Jung ,  Michael Lein ,  Glen Kristiansen ,  Carsten Stephan

    IPC分类号： G01N33/483 ,  G06F19/00 ,  G06F19/12

    CPC分类号： G01N33/4833 ,  G01N33/57434 ,  G01N2560/00 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/54 ,  G16B5/00 ,  G16H50/20 ,  Y02A90/26

    摘要： The present invention concerns means and methods for cancer diagnosis and, in particular, diagnosis of prostate cancer. Specifically, it relates to a method for diagnosing whether a subject is at risk for recunent prostate carcinoma after prostatectomy comprising determining the amount of at least one metabolite selected from Table 2 in a test sample of a subject after prostatectomy, and comparing the determined amount to a reference, whereby it is diagnosed whether the subject is at risk for recurrent prostate carcinoma after prostatectomy. Further methods provided in accordance with the present invention relate to differentiating between a malignant prostate carcinoma tissue and a non-malignant tissue and diagnosing metastasizing prostate carcinoma in a subject. Also provided are devices for carrying out the aforementioned methods.

    摘要翻译： 本发明涉及用于癌症诊断，特别是前列腺癌诊断的方法和方法。 具体地说，本发明涉及一种用于诊断受试者是否处于前列腺切除术后残留前列腺癌风险的方法，其包括在前列腺切除术后测定受试者的测试样品中选自表2的至少一种代谢物的量，并将确定的量与 作为参考，由此诊断该受试者在前列腺切除术后是否存在复发性前列腺癌的风险。 根据本发明提供的其它方法涉及区分恶性前列腺癌组织和非恶性组织并诊断受试者中转移性前列腺癌。 还提供了用于执行上述方法的装置。

    DETECTORS OF SERUM BIOMARKERS FOR PREDICTING OVARIAN CANCER RECURRENCE
    145.
    发明申请
    DETECTORS OF SERUM BIOMARKERS FOR PREDICTING OVARIAN CANCER RECURRENCE 有权
    血清生物标志物检测器预测OVARIAN癌症复发

    公开(公告)号：US20150139980A1

    公开(公告)日：2015-05-21

    申请号：US14398773

    申请日：2013-05-06

    申请人： Michael Tainsky ,  Madhumita Chatterjee ,  Gregory Dyson ,  Nancy Levin

    发明人： Michael Tainsky ,  Madhumita Chatterjee ,  Gregory Dyson ,  Nancy Levin

    IPC分类号： G01N33/574 ,  G01N33/564 ,  C07K16/32

    CPC分类号： G01N33/57449 ,  C07K16/32 ,  G01N33/564 ,  G01N2800/52 ,  G01N2800/54

    摘要： Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.

    摘要翻译： 用于检测与卵巢癌复发相关的自身抗体生物标志物的存在的多肽标记抗原，每种多肽标记抗原特异性结合至少一种自身抗体标记物。 用于检测与卵巢癌复发相关的自身抗体生物标志物的存在的抗体结合测定法，以及用于进行测定的方法。 卵巢癌患者卵巢癌复发的方法。 通过其对多肽标记抗原的亲和力分离卵巢癌特异性抗体的方法和通过该方法分离的抗体。

    PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER
    147.
    发明申请
    PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER 审中-公开
    乳腺癌的蛋白质生物标志物

    公开(公告)号：US20150005182A1

    公开(公告)日：2015-01-01

    申请号：US13932843

    申请日：2013-07-01

    申请人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    发明人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    IPC分类号： G01N33/68

    CPC分类号： G01N33/57415 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/60

    摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as “companion diagnostic” proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.

    摘要翻译： 该专利申请公开并描述了在初步诊断后不会引起复发性乳腺癌疾病的原发性乳腺癌细胞和初次诊断后引起复发性乳腺癌疾病的原发性乳腺癌细胞之间发现差异表达的蛋白质。 这些蛋白质可以在乳腺癌患者的各种生物样品的诊断和预后蛋白质测定中单独使用或以特定组合使用，以指示乳腺癌患者的癌症在初步诊断和治疗后将复发的可能性。 确定这些蛋白质的差异表达也可用于指示额外的治疗方法来抵抗复发性乳腺癌的可能性。 可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽作为这些蛋白质的报告物进行测定。 这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达的蛋白质也可以用作乳腺癌的治疗干预的靶标。 本文还公开和描述的是来自蛋白质的肽的同位素标记形式。